Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Prophylaxis for aGVHD in Aplastic Anemia HSCT
NCT05914714Phase 2Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Status: unknown.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05914714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914714.